Biomira Initiates Phase I Trial of PX-478 for Advanced Metastatic Cancers
Biomira announced that the first patient has been enrolled in a Phase I clinical trial of PX-478 in patients with advanced metastatic cancer.
PX-478 is a novel small molecule compound designed to inhibit the activity of hypoxia inducible factor-1 alpha, a transcription factor that controls the expression of a number of genes important for growth and survival of cancer cells.
Biomira said it expects to enroll a maximum of 36 patients with advanced solid tumors or lymphoma who have failed or are intolerant of standard therapy. PX-478 will be administered orally on days one through five of a 21-day cycle.
Primary objectives of the study include establishment of a maximum tolerated dose, evaluation of safety and analyses of pharmacodynamic and pharmacokinetic profiles of PX-478, the companies said.